Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
KERX Keryx Biopharmaceuticals Inc
Volgen
Ik ben ook ingestapt Genkie. gekocht op 7.09
Gaat weer lekker hier, 11,53$ . Het begint weer te kriebelen om te verkopen, ze zijn nu 56 keer meer waard als toen ik ze kocht. Ik verwacht ze volgend jaar rond de 25 als zerenex goedgekeurd is door de fda en de verkoop start.
deze week weer een partij bijgekocht. Ik hoop dat ze hetzelfde trackrecord volgen als cldx (wat een topper dit jaar) +500%
Had cldx ook en heb ze verkocht aan 12 dollar omdat ik ze toen al te duur vond. Had ze gekocht aan 4,5 dollar. Daarom dat ik t nu ook zo moeilijk vind om te verkopen. Heb me gisteren nog wat clsn bijgekocht en vandaag nog wat zlcs.
CTIC is ook een potentiële kanshebber. Bedrijf heeft nagenoeg geen schulden. Toch uitzonderlijk voor biotech
Keryx Biopharma (NASDAQ: KERX) announced that the U.S. Food and Drug Administration (FDA) approved Ferric Citrate (formerly known as Zerenex) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. "We are thrilled with the FDA's decision to approve Ferric Citrate, and look forward to bringing it to market in the U.S. within the next 12 weeks," said Ron Bentsur, Chief Executive Officer of Keryx. "We are committed to bringing innovative therapies to the market for patients with kidney disease and are excited to be offering this important treatment option to dialysis patients." The U.S. approval of Ferric Citrate was based on data from its Phase 3 registration program. In the Phase 3 clinical trials, Ferric Citrate effectively reduced serum phosphorus levels to well within the KDOQI guidelines range of 3.5 mg/dL to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Ferric Citrate's pharmacodynamic properties resulted in increased ferritin and transferrin saturation (TSAT); whereas these parameters remained relatively constant in patients treated with active control (Renvela® and/or Phoslo®). The most common adverse events for Ferric Citrate treated patients were gastrointestinal-related, including diarrhea, nausea, vomiting and constipation. "I believe that Ferric Citrate offers clear benefits to patients and represents a new way for physicians to manage hyperphosphatemia," said Julia Lewis, MD, lead investigator, nephrologist and Professor of Medicine at Vanderbilt University Medical Center. "Given Ferric Citrate's pharmacodynamic properties that lead to increases in iron stores, physicians should assess and monitor iron parameters and may need to reduce the dose of or discontinue IV iron therapy." Recently, the Company was informed by the FDA that approval of the brand name Zerenex had been rescinded. Keryx believes the Company will have an approved brand name on or prior to launch, although a brand name is not a pre-requisite for the launch of an FDA-approved drug.
Vorige week aangekocht aan € 6,91 dank@Sanderus UPDATE: Keryx Biopharma (KERX) Could Be Worth $1-$1.2 Billion In M&A Deal Updated - July 3, 2017 9:37 AM EDT) (updated to add add comments on guidance raise) Raymond James maintains Outperform on Keryx Biopharma (NASDAQ: KERX) price target of $9.00. Analyst Reni Benjamin said the company could fetch over a $1 billion in a deal which may occur before the company releases Pdufa data in November according to an email reviewed by Street Insider. That would be a premium of nearly 20% over the current market capitalization of $805 million. Benjamin comments that should strong prescription trends persist "we believe they will likely need to raise guidance ." Benjamin speculated that possible suitors could be either DaVita (NYSE: DVA), Sanofi (NYSE: SNY) or Vifor Frensenius, the JV operation between Vifor Pharma and Fresenius Medical Care (NYSE: FMS). He says that as biotech firms reach commercialization there has been chatter for the potential for M&A. For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Piddybull schreef op 4 juli 2017 00:02 :
Vorige week aangekocht aan € 6,91
dank@Sanderus
UPDATE: Keryx Biopharma (KERX) Could Be Worth $1-$1.2 Billion In M&A Deal Updated - July 3, 2017 9:37 AM EDT) (updated to add add comments on guidance raise) Raymond James maintains Outperform on Keryx Biopharma (NASDAQ: KERX) price target of $9.00. Analyst Reni Benjamin said the company could fetch over a $1 billion in a deal which may occur before the company releases Pdufa data in November according to an email reviewed by Street Insider. That would be a premium of nearly 20% over the current market capitalization of $805 million.
Benjamin comments that should strong prescription trends persist "we believe they will likely need to raise guidance ." Benjamin speculated that possible suitors could be either DaVita (NYSE: DVA), Sanofi (NYSE: SNY) or Vifor Frensenius, the JV operation between Vifor Pharma and Fresenius Medical Care (NYSE: FMS). He says that as biotech firms reach commercialization there has been chatter for the potential for M&A. For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Zeker een interessant aandeel, staan op de radar. Een premie van 20% is mager, dacht eerder aan $14/15, koersen van 2014/2015. Het medicijn trekt aan nadat het weer op de markt is gekomen, geen problemen meer met de makers. Benieuwd naar de aanstaande cijfers. Gr
Gaat vandaag goed, een nieuwe 52wks high op een goed volume. RT 8,05.
Ik zit er nu erg behoorlijk in. Sinds vorige week verhoogd tot 45 % van mijn huidige portefeuille. Vrijdag heeft het ook op vrij hoog volume alle kanten uitgedraaid om op hetzelfde niveau te eindigen. Namelijk : $ 7,86 Als ik goed geïnformeerd ben zouden de Q2 cijfers begin augustus moeten vrijgegeven worden. Daarna is de belangrijkste datum 06 november voor de PDUFA Aantal scripts vorige week : IMS 999
Why Keryx Biopharmaceuticals Stock Soared 11.6% Higher in June ! Sales are finding their footing at this biotech, and optimism is increasing ahead of an important FDA decision later this year. Todd Campbell (TMFEBCapital) Jul 8, 2017 at 6:31AM What happened ? After the biotech issued an update on its first-quarter progress in May, investors continued buying Keryx Pharmaceuticals (NASDAQ:KERX) shares in June, sending them 11.6% higher last month, according to S&P Global Market Intelligence. So what Keryx Biopharmaceuticals was once a high-flying biotech star, but its reliance on one commercial drug caused shares to crash when sales were slow to grow and production difficulties crimped prescriptions in 2016. Now, it appears Keryx Biopharmaceuticals is regaining some of its luster. The company's lone drug is Auryxia, a treatment that removes excess phosphorous from chronic kidney disease patients on dialysis. Phosphorous can build up in these patients, stripping away calcium from bones, weakening them, and potentially creating calcium deposits that can cause heart disease. Auryxia launched to nine-figure sales projections, but net product sales totaled only $27.2 million in 2016. This year, however, Auryxia may begin to get closer to analysts' rosy outlook. In Q1, net product sales in the U.S. were $10.5 million, and management thinks that full-year 2017 net product sales will come in between $56 million and $60 million. Sales could grow much bigger than that in 2018, however, if the FDA approves Auryxia's use in stage 3 to 5 chronic kidney disease patients not on dialysis. In phase 3 trials, Auryxia helped treat anemia in these patients, and the FDA has set a target action PDUFA date of Nov. 6 to decide on whether to expand the drug's label . If it does, then it will significantly increase Auryxia's addressable patient population ! An estimated 1.6 million Americans with stage 3 to 5 non-dialysis dependent chronic kidney disease have iron deficiency anemia. Now what Despite revenue gaining momentum, Keryx Biopharmaceuticals continues to lose money. In Q1, spending led to a loss of $23 million and cash burn of $21 million. As a result, the company's balance of cash and cash equivalents has fallen to $90.9 million. There isn't a cash crunch yet, but Keryx could end up tapping equity markets with a stock offering later this year if sales fall shy of projections or the FDA passes on approving the expanded label. Nevertheless, Keryx Biopharmaceuticals is an intriguing stock for bargain hunters to consider buying. The company's $850 million market cap isn't too rich of a valuation (assuming the FDA allows expanded use of Auryxia), and an argument can be made that a suitor could come knocking on its door if the FDA gives it a green light in November . Todd Campbell has no position in any stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Bron : www.fool.com/investing/2017/07/ ... -high.aspx
Met dank aan SanderusWill patience (finally) pay off? Keryx Pharmaceuticals' Auryxia won FDA approval in 2014, but so far, the drug has been more of a commercial dud than a stud. Auryxia reduces phosphorous levels in chronic kidney disease patients on dialysis, and while Auryxia's oral dosing offers advantages to existing phosphate binders, it's struggled to gain a toehold in the indication. Auryxia's net product sales were just $27.2 million last year, which is less than 3% of what Sanofi's Renagel and Renvela -- the most common phosphate binders -- hauled in during 2016. Obviously, Auryxia's performance so far has been disappointing, but there's evidence that demand for the drug is picking up, and that sales could accelerate in the coming couple of years. Auryxia's sales were $10.5 million in Q1, and this year, management thinks sales will exceed $56 million. Revenue could climb even higher in 2018 if the FDA decides to expand Auryxia's label in November. In trials, Auryxia boosted iron levels in non-dialysis patients with stage 3 to 5 chronic kidney disease (CKD). There are 1.6 million patients with CKD in these stages who have iron deficiency anemia, and thus, an approval would significantly increase Auryxia's addressable market. Keryx Biopharmaceuticals shares have more than doubled from their lows, but a market cap of less than $900 million may not adequately reflect Auryxia's peak sales potential, if it gets an FDA green light later this year. Nu Donderdag normaal voorbeurs cijfers op website Keryx Zeer benieuwd naar koersverloop daaropvolgend. FDA : 06 November blijft wel belangrijkere trigger !
Nieuw twitteraccount sinds 08 augustus LL. twitter.com/KeryxBio Nog 76 dagen of slechts 54 handelsdagen voor 06 november
KERYX BIOPHARMACEUTICALS TO WEBCAST ITS PRESENTATIONS AT INVESTOR HEALTHCARE CONFERENCES IN SEPTEMBER 2017 BOSTON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced it will webcast corporate presentations at the following investor conferences in September: A fireside chat at Morgan Stanley’s Global Healthcare Conference in New York City on Tuesday, September 12, 2017 at 12:55 p.m. EDT. Cantor Fitzgerald’s Global Healthcare Conference in New York City on Monday, September 25, 2017 at 4:45 p.m. EDT. Ladenburg Thalmann’s 2017 Healthcare Conference in New York City on Tuesday, September 26 at 11:30 a.m. EDT. Live audio webcasts of the presentations will be accessible from Keryx Biopharmaceuticals’ website at investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentations.
Keryx Biopharmaceuticals Announces Changes to its Board of Directors Date(s): 13-Sep-2017 4:11 PM Mark Enyedy appointed to Keryx's board of directors Current Keryx board member Michael Rogers appointed chairman BOSTON, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced the appointment of Mark J. Enyedy as an independent member of the company's board of directors. Mr. Enyedy brings extensive biopharmaceutical leadership experience to the company. John Butler, chairman of the Keryx board of directors and president and chief executive officer of Akebia Therapeutics, Inc., has resigned from Keryx's board. Current Keryx board member Michael Rogers has been appointed as chairman of the board. These changes are effective immediately. "On behalf of the entire board, we look forward to Mike's chairmanship and thank John for his contributions to our company," said Greg Madison, president, chief executive officer and board member of Keryx Biopharmaceuticals. "We are thrilled to have Mark join our board. His experience building leading biopharmaceutical organizations will be invaluable to Keryx as we work to pursue our vision of building a leading multi-product company focused on kidney disease." "Keryx has a unique opportunity, as it prepares for the potential launch of an additional indication for Auryxia, to help more than one million adults with chronic kidney disease in the United States manage two complications of this illness," said Mr. Enyedy. "Auryxia has all of the characteristics of a foundational medicine from which Keryx can build a leading multi-product company focused on improving outcomes for people with kidney disease. I look forward to working with the Keryx team in realizing this vision." "It has been a pleasure to work with the Keryx team," said Mr. Butler. "I am proud of our accomplishments during my time on the board and I look forward to following the company's continued success." Mr. Enyedy has more than 25 years of combined general management, business development, and legal experience in the biotechnology industry across multiple therapeutic areas. He currently serves as president and chief executive officer of ImmunoGen, Inc., a position he has held since 2016. Prior to ImmunoGen, Mr. Enyedy served as executive vice president and head of corporate development for Shire plc leading the company's strategy, merger and acquisitions, and corporate planning functions and providing commercial oversight for the company's pre-Phase 3 portfolio. Previously, Mr. Enyedy served as chief executive officer of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, and president of the transplant, oncology, and multiple sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the board of directors of Fate Therapeutics. Pursuant to the company's October 2015 financing transaction with The Baupost Group, LLC., Mr. Enyedy replaces Mr. Butler as Baupost's board appointee.
Zijn er hier nog met Keryx in portefeuille ??
Nog 1 maand ! $ 7,10 17 mio short
Nog één nacht !!! Hopelijk goedkeuring en stevige winst ! We zullen het snel merken.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
876,37
+0,27%
EUR/USD
1,0726
+0,26%
FTSE 100
8.096,61
+0,70%
Germany40^
17.994,30
-0,52%
Gold spot
2.326,71
+0,46%
NY-Nasdaq Composite
15.712,75
+0,10%
Stijgers
Dalers